

Experts seek to standardize treatments for childhood rheumatic diseases

January 15 2018

Pediatric rheumatic diseases are a varied group of rare diseases including juvenile forms of arthritis, lupus, fibromyalgia, and other conditions. Currently, there is considerable variability in how patients with these diseases are treated in clinical practice, making it difficult to understand which therapies work best. A new review article in *Arthritis & Rheumatology* examines recent efforts to address this challenge.

Ideally, randomized placebo-controlled clinical trials are conducted to help determine the best course of action against a [disease](#), but such trials are difficult to perform in [rare diseases](#). Consensus [treatment](#) plans (CTPs) are a potential alternative. CTPs are standardized strategies that are developed by a consensus among experts and are intended to help reduce treatment variability and allow for comparisons of different therapies. The Childhood Arthritis and Rheumatology Research Alliance (CARRA), the largest pediatric rheumatology research collaborative in North America, is pioneering the use of CTPs to standardize the common treatments for pediatric rheumatic diseases.

In their review, Sarah Ringold, MD, MS, of Seattle Children's Hospital, and her colleagues present the rationale for the CARRA CTP approach, consider its advantages and disadvantages, and introduce related ongoing research.

"Once a diagnosis is made, providers and [patients](#) and their families can choose together the CTP strategy that they believe will work the best for that [disease](#)," Dr. Ringold explained. "Information on how the patient is

doing on that [treatment](#) is then collected at regular clinic visits through a registry. At the end of the proposed study duration, researchers can then compare how the patients do between the different CTPs."

Dr. Ringold noted that ongoing large-scale studies are testing this approach in [juvenile idiopathic arthritis](#). Results from these studies will provide more information on the feasibility of this [approach](#) and may provide insights on which therapeutic strategies are most likely to be successful for certain [patients](#). "The CTP [approach](#) will be even more powerful when coupled with biospecimen collection to facilitate translational research aimed at identifying biomarkers of response and non-response, paving the way towards personalized medicine," she said.

More information: Sarah Ringold et al, The Childhood Arthritis & Rheumatology Research Alliance Consensus Treatment Plans: Towards Comparative Effectiveness in the Pediatric Rheumatic Diseases, *Arthritis & Rheumatology* (2018). [DOI: 10.1002/art.40395](https://doi.org/10.1002/art.40395)

Provided by Wiley

Citation: Experts seek to standardize treatments for childhood rheumatic diseases (2018, January 15) retrieved 3 May 2024 from <https://medicalxpress.com/news/2018-01-experts-standardize-treatments-childhood-rheumatic.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.